Kala Pharmaceuticals reveals Phase 1b clinical trial data for KPI-012
Category: #health  By Pankaj Singh  Date: 2022-05-02
 | 
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Kala Pharmaceuticals reveals Phase 1b clinical trial data for KPI-012

Kala Pharmaceuticals Inc., a commercial-stage biopharma company, has reportedly presented data from the Phase 1b clinical trial of KPI-012, its cell-free secretome therapy for treating impaired healing-driven severe ocular diseases.

According to previous revelations, KPI-012 treatment was well tolerated and resulted into substantial improvements in patients with various PCED (persistent corneal epithelial defect) aetiologies, with complete PCED healing in six out of eight evaluable patients.

The data will be presented in a poster session at the 2022 ARVO (Association for Research in Vision and Ophthalmology) Annual Meeting.

Commenting on the reported data, Phase 1b trial investigator Valeria Sánchez-Huerta, M.D. FACS, Medical Director at Association to Prevent Blindness in Mexico, cited that PCED is an impaired corneal healing disease and can cause infection, irreversible vision loss, and corneal perforation if left untreated.

It is remarkable to attain complete and rapid wound healing along with reduction in pain associated with PCED as well as an enhancement in corneal opacity and visual acuity, in patients with underlying aetiologies, especially after a short treatment time.

Based on these early insights, it can be estimated that KPI-012 could be the first treatment to acknowledge PCED across all aetiologies.

Interestingly, PCED is a rare disease with an approximate incidence of 100,000 in the United States every year.

It can have different aetiologies including surgical epithelial debridement, neurotrophic keratitis, corneal transplant, microbial/viral keratitis, mechanical and chemical trauma, along with limbal stem cell deficiency. This can lead to corneal perforation, ulceration, secondary infections, stromal scarring, and significant loss of vision.

Recovery after a corneal injury follows a thorough process comprising cell signalling, growth factors, migration, proliferation, and extracellular matrix remodelling.

In PCED patients, there is an imbalance of important biomolecules, including cytokines, and growth factors, which leads to impaired innervation, disruption of the stromal and epithelial layers, and substantial inflammation.

Source credits: https://www.globenewswire.com/news-release/2022/05/01/2433063/0/en/Kala-Pharmaceuticals-to-Present-Clinical-Data-for-KPI-012-its-Mesenchymal-Stem-Cell-Secretome-Product-for-the-Treatment-of-PCED-at-the-2022-ARVO-Annual-Meeting.html



About Author

Pankaj Singh

Email: [email protected]   linkdin twitter

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

More News By Pankaj Singh

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

Rona Therapeutics obtains global rights to Sanofi's siRNA platform

By Pankaj Singh

Rona Therapeutics Inc has reportedly acquired the global exclusive rights to the siRNA platform of delivery moiety and chemical modification from Sanofi S.A., in addition to four pre-clinical contenders for unrevealed ...

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

Toy maker Mattel inks multi-year agreement with Elon Musk’s SpaceX

By Pankaj Singh

California-based toy manufacturing and entertainment company, Mattel, has recently signed a multi-year agreement with Elon Musk’s private spaceflight company, SpaceX.

T...

USHV partners with Willowbrook to provide quality cardiovascular care

USHV partners with Willowbrook to provide quality cardiovascular care

By Pankaj Singh

US Heart & Vascular (USHV) is reportedly partnering with Willowbrook Cardiovascular Associates to offer quality cardiovascular care in the Houston market.

USHV has a strong ma...